Clinical Research Directory
Browse clinical research sites, groups, and studies.
Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis
Sponsor: University Hospital, Montpellier
Summary
Prognosis of resectable early stages NSCLC might be improved by a better knowledge of post-operative minimal residual disease (MRD). This could be achieved by studying patient with stage I to IIIA completely resected-NSCLC, comparing qualitative and quantitative features of pre- and post-operative circulating cell-free DNA (cirDNA), using MiTest. We assume that the evolution of the parameters of MiTest and relapse rate after surgery are related and expect to prove that normalization of MiTest at one month after surgery is a prognostic factor of reduced relapse at one year.
Official title: Local Undertaking of Resected Non-small Cell Lung Cancer by Generating a Residual Disease Outline Based on Circulating Cell-free DNA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
133
Start Date
2022-02-15
Completion Date
2026-12-31
Last Updated
2025-12-03
Healthy Volunteers
No
Conditions
Interventions
Blood sample
Pre- and postoperative blood sample
Locations (1)
University Hospital
Montpellier, France